Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.18 USD
Change Today -0.02 / -0.91%
Volume 1.4M
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

synta pharmaceuticals corp (SNTA) Snapshot

Open
$2.19
Previous Close
$2.20
Day High
$2.22
Day Low
$2.13
52 Week High
07/7/14 - $4.97
52 Week Low
03/31/15 - $1.85
Market Cap
293.0M
Average Volume 10 Days
1.2M
EPS TTM
$-0.81
Shares Outstanding
134.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SYNTA PHARMACEUTICALS CORP (SNTA)

synta pharmaceuticals corp (SNTA) Related Businessweek News

No Related Businessweek News Found

synta pharmaceuticals corp (SNTA) Details

Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the research, development, and commercialization of novel oncology medicines for cancer patients. Its lead oncology drug candidate includes ganetespib, an Hsp90 inhibitor, which is in Phase III clinical trial for the treatment of non-small cell lung cancer; in Phase II clinical trial for patients with hormone receptor positive metastatic breast cancer; in Phase I clinical trial for the treatment of HER2 positive patients with metastatic breast cancer; in Phase II/III clinical trial for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome; in Phase I/II trial of paclitaxel in combination with ganetespib in patients with platinum-resistant ovarian cancer; and in Phase I/II trial in combination with the mTOR inhibitor sirolimus in patients with refractory sarcoma. The company’s product pipeline also comprises Hsp90-inhibitor Drug Conjugate, a novel, proprietary small molecule cancer drug development program; Elesclomol, a mitochondria-targeting agent that is in Phase II clinical trial for ovarian cancer; and CRACM ion channel inhibitors and IL-12/23 inhibitors for the treatment of inflammatory diseases. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts.

110 Employees
Last Reported Date: 03/12/15
Founded in 2000

synta pharmaceuticals corp (SNTA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $77.5K
Executive Chairman, Chairman of Nominating & ...
Total Annual Compensation: --
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $21.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $530.3K
Senior Vice President of Human Resources
Total Annual Compensation: $387.9K
Compensation as of Fiscal Year 2014.

synta pharmaceuticals corp (SNTA) Key Developments

Synta Pharmaceuticals Corp. Presents at BIO International Convention 2015, Jun-17-2015 03:30 PM

Synta Pharmaceuticals Corp. Presents at BIO International Convention 2015, Jun-17-2015 03:30 PM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Chen Schor, Chief Executive Officer, President and Director.

Synta Pharmaceuticals Corp. Announces Ganetespib Program Updates

Synta Pharmaceuticals Corp. announced the updates to its clinical program for Ganetespib, a next-generation inhibitor of the chaperone protein Hsp90. Ganetespib is currently being studied in several large, randomized studies, including the Phase 3 GALAXY-2 trial in non-small cell lung cancer, as well as a number of other investigator-sponsored studies in various malignancies, including acute myeloid leukemia, breast cancer and ovarian cancer. The company announced that the first patient has been enrolled in the Phase 2 portion of the GANNET53 study, a randomized, pan-European study evaluating the combination of ganetespib and paclitaxel vs. paclitaxel alone in over 200 patients with metastatic, predominantly p53 mutant, platinum-resistant ovarian cancer. Enrollment in the Phase 2 portion follows the successful completion of Phase 1, the results of which were recently presented at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago. The Phase 1 data demonstrated that the combination of ganetespib 150 mg/m² with paclitaxel 80 mg/m² once weekly for 3 out of 4 weeks was generally well tolerated, with no dose limiting toxicities, and was therefore chosen for the randomized phase 2 trial. GANNET53 is sponsored by Innsbruck Medical University in Austria and funded by the European Commission. The company also announced that results from the Phase 2 GALAXY-1 trial, a global, randomized, multi-center study designed to identify the patients with advanced non-small cell lung cancer most likely to benefit from second-line treatment with ganetespib in combination with docetaxel versus docetaxel alone, have been published in the journal Annals of Oncology. As previously announced, a pre-specified stratification factor analysis demonstrated that patients diagnosed with advanced non-small cell lung adenocarcinoma more than six months prior to study entry derived the most benefit from combination treatment, leading to the selection of this population for the ongoing Phase 3 GALAXY-2 trial. Based on current projections and statistical assumptions, the first interim overall survival (OS) analysis of GALAXY-2 is on track to occur in the second half of 2015, and the second interim and final OS analyses will be conducted in 2016.

Synta Pharmaceuticals Corp. Announces Phase 1 Clinical Results from Three Investigator-Sponsored Trials Evaluating Ganetespib Combination Therapy in ALK-Positive Lung Cancer

Synta Pharmaceuticals Corp. announced that Phase 1 clinical results from three investigator-sponsored trials evaluating ganetespib combination therapy in ALK-positive lung cancer, platinum-resistant ovarian cancer, and rectal cancer will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 29-June 2 in Chicago. Ganetespib, a next-generation inhibitor of the chaperone protein Hsp90 critical for the activation of numerous proteins that control malignant tumor growth, is currently in Phase 3 evaluation in non-small cell lung cancer. The company also announced that preclinical results for its lead HDC candidate, STA-12-8666, in pediatric sarcoma will be presented at the ASCO Annual Meeting. STA-12-8666 is a conjugate of an Hsp90 inhibitor and SN-38, the active metabolite of the widely used drug irinotecan.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNTA:US $2.18 USD -0.02

SNTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SNTA.
View Industry Companies
 

Industry Analysis

SNTA

Industry Average

Valuation SNTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYNTA PHARMACEUTICALS CORP, please visit www.syntapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.